Shares of Mangoceuticals surged in pre-open trading, rising 31.9% to $0.5612, after an announcement from its pending merger partner, Nuclea Energy Inc., regarding a regulatory and siting milestone for the Morpheus microreactor program.
Nuclea said it had signed a memorandum of understanding to explore siting a nuclear test reactor for the Morpheus microreactor at the Utah San Rafael Energy Lab. The MOU is intended to advance development work on the Morpheus microreactor, a transportable, factory-built micro-modular reactor that uses lead cooling and graphite moderation to provide off-grid power.
Nuclea Energy is described as an Ontario-based advanced nuclear technology startup developing the Morpheus microreactor. The company’s system is positioned as a transportable reactor relying on lead as a coolant and graphite as a moderator to deliver clean, off-grid power.
The announcement carried particular weight because of the companies’ pending deal. Mangoceuticals and Nuclea entered a definitive business combination agreement on July 30 that is intended to give Nuclea a Nasdaq listing through Mangoceuticals. Mangoceuticals’ CEO, Jacob Cohen, called the MOU "meaningful progress" for the merger.
The proposed transaction remains subject to stockholder and regulatory approval. As the merger process continues to unfold, each operational milestone for Nuclea that demonstrates progress can help sustain investor confidence in completion of the business combination.
Market context suggests the pre-market rally was driven largely by company-specific news. The S&P 500 registered a modest gain of 0.2% while the Nasdaq composite was slightly negative, providing no clear macro tailwind for small-cap names. That relative lack of broader-market support indicates today’s move was linked principally to the Nuclea announcement and the pending deal narrative.
Investors and observers have also noted that Mangoceuticals is due to report earnings around August 13, which appears to have increased speculative interest in the stock. With the merger still pending and the share price trading well below its 52-week high of $2.75, the combination of deal momentum and interest in the nuclear energy theme helped drive the pre-market demand for MGRX shares.
Analysts and market participants pointed to the strategic rationale behind the tie-up: the deal is intended to give Nuclea a Nasdaq listing while offering Mangoceuticals shareholders exposure to the advanced nuclear and AI-driven power market. That thematic space has attracted attention amid rising power demand from data centers and artificial intelligence infrastructure.
In sum, the Utah MOU provides a tangible proof-of-concept milestone for the Morpheus program and reinforces the strategic rationale for the pending transaction. With the merger process still in motion and the stock trading well below prior highs, investor enthusiasm tied to operational milestones and the high-profile energy theme appears to be the dominant force behind the pre-market rally.
Market data snapshot: Pre-market price action showed a notable uptick for MGRX following the Nuclea announcement. The stock remains materially below its 52-week peak of $2.75, and the merger is still subject to customary shareholder and regulatory reviews.